November 2021

TQS-168, an investigational therapy being developed by Tranquis Therapeutics, reduced inflammation in mouse and human models of amyotrophic lateral sclerosis (ALS), and prolonged survival in the mice, according to a preclinical study.   Based on these findings, Tranquis is moving the therapy into Phase 1 clinical studies.   “We believe TQS-168 represents a new class […]

“All the Bush League batters Are left to die on the diamond In the stands the home crowd scatters For the turnstiles.”   Twice in my post-ALS life, Neil Young’s song “For the Turnstiles” has struck me smack dab in the center of my forehead.   As the dust finally settled following my ALS diagnosis,

A Phase 2 study of the investigational antibody AT-1501 in treating amyotrophic lateral sclerosis (ALS) has completed patient enrollment in three of its four dosing groups, and is likely to be fully enrolled by year’s end, its developer, Eledon Pharmaceuticals, announced.   A total of 54 ALS patients diagnosed in the previous two years are

CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), failed to prevent motor neurons loss and lung function decline relative to a placebo, according to top-line data from the RESCUE-ALS Phase 2 clinical trial.   The trial, in other words, did not meet its primary and a key secondary goal after

“Well I don’t know why I came here tonight, I’ve got the feeling that something ain’t right. I’m so scared in case I fall off my chair, And I’m wondering how I’ll get down the stairs. Clowns to the left of me! Jokers to the right! Here I am stuck in the middle with you.”